This site is intended for health professionals only
Monday 20 May 2019
Share |

Topic: Fotivda

August 29, 2017
Tivozanib is indicated for the first line treatment of adult patients with advanced renal cell carcinoma and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC

EUSA Pharma has announced that the European Commission (EC) has licensed Fotivda® for the management of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland.

 

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine